Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.

The ability to identify immunogenic determinants that activate T-cells is important for the development of new vaccines, allergy therapy and protein therapeutics. In silico MHC-II binding prediction algorithms are often used for T-cell epitope identification. To understand how well those programs predict immunogenicity, we computed HLA binding to peptides spanning the sequence of PE38, a fragment of an anti-cancer immunotoxin, and compared the predicted and experimentally identified T-cell epitopes. We found that the prediction for individual donors did not correlate well with the experimental data. Furthermore, prediction of T-cell epitopes in an HLA heterogenic population revealed that the two strongest epitopes were predicted at multiple cutoffs but the third epitope was predicted negative at all cutoffs and overall 4/9 epitopes were missed at several cutoffs. We conclude that MHC class-II binding predictions are not sufficient to predict the T-cell epitopes in PE38 and should be supplemented by experimental work.

[1]  Bjoern Peters,et al.  Evaluating the Immunogenicity of Protein Drugs by Applying In Vitro MHC Binding Data and the Immune Epitope Database and Analysis Resource , 2013, Clinical & developmental immunology.

[2]  I. Pastan,et al.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome , 2014, British journal of haematology.

[3]  H. Sbai,et al.  Use of T cell epitopes for vaccine development. , 2001, Current drug targets. Infectious disorders.

[4]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[5]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[6]  Ravi V. Kolla,et al.  T Cell Responses to Known Allergen Proteins Are Differently Polarized and Account for a Variable Fraction of Total Response to Allergen Extracts , 2012, The Journal of Immunology.

[7]  Leonard Moise,et al.  A Method for Individualizing the Prediction of Immunogenicity of Protein Vaccines and Biologic Therapeutics: Individualized T Cell Epitope Measure (iTEM) , 2010, Journal of biomedicine & biotechnology.

[8]  Leonard Moise,et al.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.

[9]  Vibha Jawa,et al.  T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.

[10]  T. Strutt,et al.  Expanding roles for CD4+ T cells in immunity to viruses , 2012, Nature Reviews Immunology.

[11]  W. Paul,et al.  CD4 T cells: fates, functions, and faults. , 2008, Blood.

[12]  R. Spielman,et al.  Structure, Sequence and Polymorphism in the HLA‐D Region , 1985, Immunological reviews.

[13]  E. Wardelmann,et al.  HLA‐class II haplotype associations with ovarian cancer , 2006, International journal of cancer.

[14]  Ravi V. Kolla,et al.  Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals , 2013, Proceedings of the National Academy of Sciences.

[15]  Morten Nielsen,et al.  Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..

[16]  Bjoern Peters,et al.  Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen , 2010, The Journal of Immunology.

[17]  J. Sidney,et al.  In Silico Prediction of Peptides Binding to Multiple HLA-DR Molecules Accurately Identifies Immunodominant Epitopes from gp43 of Paracoccidioides brasiliensis Frequently Recognized in Primary Peripheral Blood Mononuclear Cell Responses from Sensitized Individuals , 2003, Molecular medicine.

[18]  Morten Nielsen,et al.  Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.

[19]  Jing Wu,et al.  In Silico Prediction of T and B Cell Epitopes of Der f 25 in Dermatophagoides farinae , 2014, International journal of genomics.

[20]  P. Stordeur,et al.  Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR. , 2005, Journal of immunological methods.

[21]  Bjoern Peters,et al.  Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes , 2011, Immunogenetics.

[22]  B. Jabri,et al.  Vaccine against autoimmune disease: antigen-specific immunotherapy. , 2013, Current opinion in immunology.

[23]  Qing Zhang,et al.  Immune epitope database analysis resource (IEDB-AR) , 2008, Nucleic Acids Res..

[24]  I. Pastan,et al.  Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.

[25]  John Sidney,et al.  Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients , 2006, AIDS.

[26]  B. Maillère,et al.  Quantitative analysis of the CD4 T‐cell repertoire specific to therapeutic antibodies in healthy donors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Bernhard Knapp,et al.  Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope Prediction , 2014, Journal of Virology.

[28]  George Georgiou,et al.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.

[29]  Morten Nielsen,et al.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.

[30]  M. Barnardo,et al.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.

[31]  N. Farid,et al.  Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D‐related 11 in Eastern Hungarians , 2005, Cancer.

[32]  John Sidney,et al.  Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.

[33]  D. Baker,et al.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.

[34]  Julie A McMurry,et al.  Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. , 2007, Current molecular medicine.

[35]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[36]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[37]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[38]  Morten Nielsen,et al.  NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.

[39]  S. Steinberg,et al.  Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression , 2013, Science Translational Medicine.

[40]  Chris Bailey-Kellogg,et al.  Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loads , 2015, Biotechnology and bioengineering.

[41]  Ronit Mazor,et al.  Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.

[42]  Wolfgang Aehle,et al.  A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.

[43]  R D Appel,et al.  Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.

[44]  S. Stevanović Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.

[45]  J. D. White,et al.  Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Rothbard,et al.  Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. , 1994, Journal of immunology.

[47]  W. Paul,et al.  How are TH2-type immune responses initiated and amplified? , 2010, Nature Reviews Immunology.

[48]  David Baker,et al.  Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.

[49]  Chris Bailey-Kellogg,et al.  Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate , 2014, Cellular and Molecular Life Sciences.

[50]  Alessandro Sette,et al.  Reverse vaccinology: developing vaccines in the era of genomics. , 2010, Immunity.

[51]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[52]  A. D. De Groot,et al.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome , 2014, Human vaccines & immunotherapeutics.

[53]  W. Wilson,et al.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  John Sidney,et al.  Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes , 2014, BCB.

[55]  M. Tilanus,et al.  Automated, solid-phase sequencing of DRB region genes using T7 sequencing chemistry and dye-labeled primers. , 1995, Tissue antigens.